159 related articles for article (PubMed ID: 19648182)
21. A novel DNA/peptide combined vaccine induces PSCA-specific cytotoxic T-lymphocyte responses and suppresses tumor growth in experimental prostate cancer.
Zhang KQ; Yang F; Ye J; Jiang M; Liu Y; Jin FS; Wu YZ
Urology; 2012 Jun; 79(6):1410.e7-13. PubMed ID: 22513035
[TBL] [Abstract][Full Text] [Related]
22. CpG oligonucleotide as an adjuvant for the treatment of prostate cancer.
Lubaroff DM; Karan D
Adv Drug Deliv Rev; 2009 Mar; 61(3):268-74. PubMed ID: 19166887
[TBL] [Abstract][Full Text] [Related]
23. Safety and immunological efficacy of a prostate cancer plasmid DNA vaccine encoding prostatic acid phosphatase (PAP).
Johnson LE; Frye TP; Arnot AR; Marquette C; Couture LA; Gendron-Fitzpatrick A; McNeel DG
Vaccine; 2006 Jan; 24(3):293-303. PubMed ID: 16115700
[TBL] [Abstract][Full Text] [Related]
24. Molecular and immunological analysis of genetic prostate specific antigen (PSA) vaccine.
Kim JJ; Trivedi NN; Wilson DM; Mahalingam S; Morrison L; Tsai A; Chattergoon MA; Dang K; Patel M; Ahn L; Boyer JD; Chalian AA; Schoemaker H; Kieber-Emmons T; Agadjanyan MA; Weiner DB
Oncogene; 1998 Dec; 17(24):3125-35. PubMed ID: 9872328
[TBL] [Abstract][Full Text] [Related]
25. Immune response to vaccination with DNA-Hsp65 in a phase I clinical trial with head and neck cancer patients.
Victora GD; Socorro-Silva A; Volsi EC; Abdallah K; Lima FD; Smith RB; Moyses RA; Zárate-Bladés CR; Michaluart P; Silva CL; Kalil J; Coelho V
Cancer Gene Ther; 2009 Jul; 16(7):598-608. PubMed ID: 19197326
[TBL] [Abstract][Full Text] [Related]
26. The enhanced anti-angiogenic and antitumor effects of combining flk1-based DNA vaccine and IP-10.
Lu XL; Jiang XB; Liu RE; Zhang SM
Vaccine; 2008 Oct; 26(42):5352-7. PubMed ID: 18723067
[TBL] [Abstract][Full Text] [Related]
27. Improved efficacy of DNA vaccination against breast cancer by boosting with the repeat beta-hCG C-terminal peptide carried by mycobacterial heat-shock protein HSP65.
Yi H; Rong Y; Yankai Z; Wentao L; Hongxia Z; Jie W; Rongyue C; Taiming L; Jingjing L
Vaccine; 2006 Mar; 24(14):2575-84. PubMed ID: 16420967
[TBL] [Abstract][Full Text] [Related]
28. Immunization with an antigen identified by cytokine tumor vaccine-assisted SEREX (CAS) suppressed growth of the rat 9L glioma in vivo.
Okada H; Attanucci J; Giezeman-Smits KM; Brissette-Storkus C; Fellows WK; Gambotto A; Pollack LF; Pogue-Geile K; Lotze MT; Bozik ME; Chambers WH
Cancer Res; 2001 Mar; 61(6):2625-31. PubMed ID: 11289140
[TBL] [Abstract][Full Text] [Related]
29. Vaccination with an adenoviral vector encoding the tumor antigen directly linked to invariant chain induces potent CD4(+) T-cell-independent CD8(+) T-cell-mediated tumor control.
Sorensen MR; Holst PJ; Pircher H; Christensen JP; Thomsen AR
Eur J Immunol; 2009 Oct; 39(10):2725-36. PubMed ID: 19637230
[TBL] [Abstract][Full Text] [Related]
30. CpG immuno-stimulatory motifs enhance humoral immune responses against hepatitis C virus core protein after DNA-based immunization.
Encke J; zu Putlitz J; Stremmel W; Wands JR
Arch Virol; 2003 Mar; 148(3):435-48. PubMed ID: 12607097
[TBL] [Abstract][Full Text] [Related]
31. Engineering enhancement of immune responses to DNA-based vaccines in a prostate cancer model in rhesus macaques through the use of cytokine gene adjuvants.
Kim JJ; Yang JS; Dang K; Manson KH; Weiner DB
Clin Cancer Res; 2001 Mar; 7(3 Suppl):882s-889s. PubMed ID: 11300487
[TBL] [Abstract][Full Text] [Related]
32. Antitumor immunity by a dendritic cell vaccine encoding secondary lymphoid chemokine and tumor lysate on murine prostate cancer.
Lu J; Zhang Q; Liang CM; Xia SJ; Zhong CP; Wang DW
Asian J Androl; 2008 Nov; 10(6):883-9. PubMed ID: 18958352
[TBL] [Abstract][Full Text] [Related]
33. [Development of oral DNA vaccine based on MG(7)-Ag mimotope of gastric cancer].
Guo C; Ding J; Yu Z; Han Q; Meng F; Liu N; Fan D
Zhonghua Zhong Liu Za Zhi; 2002 Mar; 24(2):110-3. PubMed ID: 12015027
[TBL] [Abstract][Full Text] [Related]
34. Synthetic luteinizing hormone releasing hormone (LHRH) vaccine for effective androgen deprivation and its application to prostate cancer immunotherapy.
Finstad CL; Wang CY; Kowalski J; Zhang M; Li ML; Li XM; Xia WG; Bosland MC; Murthy KK; Walfield AM; Koff WC; Zamb TJ
Vaccine; 2004 Mar; 22(9-10):1300-13. PubMed ID: 15003660
[TBL] [Abstract][Full Text] [Related]
35. Induction of immune response and anti-tumor activities in mice with a DNA vaccine encoding human mucin 1 variable-number tandem repeats.
Zhang S; Zhang H; Shi H; Yu X; Kong W; Li W
Hum Immunol; 2008; 69(4-5):250-8. PubMed ID: 18486759
[TBL] [Abstract][Full Text] [Related]
36. Tumor-specific immunity and antiangiogenesis generated by a DNA vaccine encoding calreticulin linked to a tumor antigen.
Cheng WF; Hung CF; Chai CY; Hsu KF; He L; Ling M; Wu TC
J Clin Invest; 2001 Sep; 108(5):669-78. PubMed ID: 11544272
[TBL] [Abstract][Full Text] [Related]
37. Combined therapy with flk1-based DNA vaccine and interleukin-12 results in enhanced antiangiogenic and antitumor effects.
Feng KK; Zhao HY; Qiu H; Liu JX; Chen J
Cancer Lett; 2005 Apr; 221(1):41-7. PubMed ID: 15797625
[TBL] [Abstract][Full Text] [Related]
38. Injection of DNA encoding granulocyte-macrophage colony-stimulating factor recruits dendritic cells for immune adjuvant effects.
Bowne WB; Wolchok JD; Hawkins WG; Srinivasan R; Gregor P; Blachere NE; Moroi Y; Engelhorn ME; Houghton AN; Lewis JJ
Cytokines Cell Mol Ther; 1999 Dec; 5(4):217-25. PubMed ID: 10850386
[TBL] [Abstract][Full Text] [Related]
39. Bombesin stimulates nuclear factor kappa B activation and expression of proangiogenic factors in prostate cancer cells.
Levine L; Lucci JA; Pazdrak B; Cheng JZ; Guo YS; Townsend CM; Hellmich MR
Cancer Res; 2003 Jul; 63(13):3495-502. PubMed ID: 12839933
[TBL] [Abstract][Full Text] [Related]
40. Specific cellular immunity and antitumor responses in C57BL/6 mice induced by DNA vaccine encoding murine AFP.
Tian G; Yi JL; Xiong P
Hepatobiliary Pancreat Dis Int; 2004 Aug; 3(3):440-3. PubMed ID: 15313685
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
